Article
Gastroenterology & Hepatology
Eun Mi Song, Eun Hye Oh, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Summary: Through retrospective review of 121 Korean patients with SR-ASUC, it was found that there were no significant differences in the rates of treatment failure and colectomy at 3 months between the CsA and IFX treatment groups. Additionally, prior use of azathioprine and Mayo score at the time of rescue therapy were both associated with treatment failure or colectomy within 3 months.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Gaurav Syal, Lori Robbins, Amir Kashani, Nirupama Bonthala, Edward Feldman, Phillip Fleshner, Eric Vasiliauskas, Dermot McGovern, Christina Ha, Stephan Targan, Gil Y. Melmed
Summary: Serum albumin and band neutrophil percentage are independent predictors of failure of infliximab rescue therapy in patients with acute severe ulcerative colitis. The combination of serum albumin <= 2.5 g/dl and band neutrophil count >= 13% has a 100% positive predictive value for 90-day colectomy.
DIGESTIVE DISEASES AND SCIENCES
(2021)
Article
Gastroenterology & Hepatology
David Laharie, Arnaud Bourreille, Julien Branche, Matthieu Allez, Yoram Bouhnik, Jerome Filippi, Frank Zerbib, Guillaume Savoye, Lucine Vuitton, Jacques Moreau, Aurelien Amiot, Laurent Beaugerie, Elena Ricart, Olivier Dewit, Antonio Lopez-Sanroman, Mathurin Fumery, Franck Carbonnel, Anthony Buisson, Benoit Coffin, Xavier Roblin, Gert van Assche, Maria Esteve, Martti Farkkila, Javier P. Gisbert, Philippe Marteau, Stephane Nahon, Martine de Vos, Laurent Peyrin-Biroulet, Jean-Yves Mary
Summary: In patients with steroid-refractory ASUC responding to second-line medical therapy, the process of endoscopic remission started with bleeding remission and was not achieved in half the patients at day 98 for vascular pattern. Infliximab provided a higher endoscopic remission rate than cyclosporine at day 98.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Review
Gastroenterology & Hepatology
Brigida Barberio, Christopher J. Black, Edoardo Savarino, Alexander C. Ford
Summary: The study found that both ciclosporin and infliximab were superior to placebo in terms of improving treatment response and avoiding colectomy in patients with acute glucocorticosteroid-refractory ulcerative colitis, with no significant differences in efficacy or safety between the two within 1 year.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Stefano Festa, Maria L. Scribano, Daniela Pugliese, Cristina Bezzio, Mariabeatrice Principi, Davide G. Ribaldone, Mariangela Allocca, Giammarco Mocci, Giorgia Bodini, Rocco Spagnuolo, Piero Vernia, Silvia Mazzuoli, Francesco Costa, Brigida Barberio, Rocco Cosintino, Giulia Zerboni, Annalisa Aratari, Alessandro Armuzzi, Claudio Papi
Summary: Long-term follow-up of patients with acute severe ulcerative colitis who avoided early colectomy showed that the majority of patients did not require immediate surgery. Patients who responded to steroids or rescue therapy had a lower risk of long-term colectomy, while those previously exposed to antitumour necrosis factor-alpha agents or with refractory cases during acute attacks had a higher risk of long-term colectomy.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2021)
Article
Gastroenterology & Hepatology
Jared A. Sninsky, Ana-Maria Staicu, Edward L. Barnes
Summary: In steroid-refractory patients with acute severe ulcerative colitis, the number of advanced therapies prior to admission and day 3 C-reactive protein post-rescue therapy is associated with a higher risk of colectomy within 12 months.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Gastroenterology & Hepatology
Christopher F. D. Li Wai Suen, Dean Seah, Matthew C. Choy, Peter De Cruz
Summary: Acute severe ulcerative colitis (ASUC) is a medical emergency that may require colectomy in patients who do not respond to rescue therapy. This study aimed to identify factors associated with response to rescue therapy in adults with ASUC and suggest future research directions. The findings highlight several clinical, hematological, biochemical, endoscopic, and pharmacological factors that predict response to rescue therapy and provide insights for clinical decision-making and improving outcomes.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Gastroenterology & Hepatology
Javier P. Gisbert, Maria Jose Garcia, Maria Chaparro
Summary: For patients with steroid-refractory ASUC, both standard treatment (cyclosporine and infliximab) and newly developed agents (such as vedolizumab and ustekinumab) are effective options.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Medicine, General & Internal
Cristina Calvino-Suarez, Rocio Ferreiro-Iglesias, Iria Baston Rey, Manuel Barreiro-de Acosta
Summary: Management of ulcerative colitis after surgery (total proctocolectomy with ileal-pouch anal anastomosis) is challenging as patients experience uncomfortable symptoms, especially pouchitis. The etiology of chronic pouchitis remains unknown, making it difficult to treat. Antibiotics, budesonide, and biological therapies are recommended, but some may still require a permanent ileostomy.
FRONTIERS IN MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Abhishek Bhurwal, Carlos D. Minacapelli, Anish Patel, Hemant Mutneja, Akshay Goel, Ishani Shah, Vikas Bansal, Bhaumik Brahmbhatt, Kiron M. Das
Summary: This study revealed racial and geographical disparities in colectomy rates among hospitalized patients with UC after the introduction of anti-TNF therapy. African American and Hispanic patients had significantly lower colectomy rates compared to White patients, while the western regions of the United States had the highest colectomy rates. Further research is needed to understand the underlying social and biological factors contributing to these disparities.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Jeffrey A. Berinstein, Jessica L. Sheehan, Michael Dias, Elliot M. Berinstein, Calen A. Steiner, Laura A. Johnson, Randolph E. Regal, John I. Allen, Kelly C. Cushing, Ryan W. Stidham, Shrinivas Bishu, Jami A. R. Kinnucan, Shirley A. Cohen-Mekelburg, Akbar K. Waljee, Peter D. R. Higgins
Summary: The study suggests that tofacitinib with concomitant intravenous corticosteroids may reduce the risk of colectomy in ASUC patients, especially with a dosage of 10 mg three times daily. Rates of complications and steroid dependence were similar between the tofacitinib group and controls. Prospective trials are needed to further investigate the safety and optimal dosing of tofacitinib in ASUC patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Review
Medicine, General & Internal
Yangyang Duan, Xueqi Wang, Qiubo Li, Shijiang Sun, Xi Liang, Huijing Li, Jing Huang, Tianhe Zhao, Jingnan Hu, Jianxin Liu, Zhenbiao Hu, Jianming He
Summary: Infliximab, cyclosporine, and tacrolimus are effective salvage therapies for ulcerative colitis. Tacrolimus has the highest efficacy in achieving long-term clinical remission, while cyclosporine is the most cost-effective option compared to infliximab or tacrolimus.
Review
Gastroenterology & Hepatology
Nick Dai, Omar Haidar, Alan Askari, Jonathan P. Segal
Summary: This study aimed to understand the changing prevalence of colectomy in Ulcerative Colitis (UC) over time. The results showed that the overall colectomy rate has decreased over the past three decades. Biologics may have played a role in reducing the risk of colectomy, but the relative risk reduction is likely to be modest.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Deloshaan Subhaharan, Pradeep Kakkadasam Ramaswamy, Laura Willmann, Hadi Moattar, Maneesha Bhullar, Naveed Ishaq, Alexander Dorrington, Dheeraj Shukla, Carolyn McIvor, John Edwards, Waled Mohsen
Summary: This study aimed to assess the non-response rates to steroids during the index admission for acute severe ulcerative colitis (ASUC) in older adults (>= 60 years of age). The study found that the non-response rates were similar in older adults and patients younger than 60 years of age. Additionally, the response to medical rescue therapy and the colectomy rates were also similar between the two groups.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Revanth S. Kosaraju, Daniel J. Wong, Eve M. Roth, Thomas E. Cataldo, Anne C. Fabrizio, Kristen T. Crowell, Joseph D. Feuerstein, Evangelos Messaris
Summary: This study compared the colectomy and postoperative complication rates in hospitalized patients with severe ulcerative colitis receiving standard infliximab induction therapy and dose-intensified regimens. The results showed no significant difference in colectomy rates between the two treatment approaches, and dose-intensified regimens were not associated with a greater risk of perioperative complications.
DISEASES OF THE COLON & RECTUM
(2022)
Article
Gastroenterology & Hepatology
Anders Forss, Mark Clements, Par Myrelid, Hans Strid, Charlotte Soderman, Agnieszka Wagner, David Andersson, Fredrik Hjelm, Ola Olen, Jonas Halfvarson, Jonas F. Ludvigsson
Summary: This study demonstrates the long-term clinical effectiveness of ustekinumab in patients with active Crohn's disease, as well as its improvement in Health-related Quality of Life (HRQoL) measures.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Dentistry, Oral Surgery & Medicine
Stina Hansson, Eva Josefsson, Rune Lindsten, Anders Magnuson, Farhan Bazargani
Summary: This study evaluated the perceived pain intensity, discomfort, functional jaw impairment, and analgesic consumption in patients with unilateral posterior crossbite treated with either RME or QH appliances in the early mixed dentition. The results showed that patients in the QH group experienced higher pain from the tongue and chafe from the appliance on the first day of treatment, and the chafe from the appliance was still higher on the fourth day. Speech was affected in both groups on day 1, but the impairment was significantly higher in the RME group on days 4 and 7. There was no significant difference in analgesic consumption between the groups at any time. The majority of patients reported low to moderate pain and discomfort based on the visual analogue scale values.
EUROPEAN JOURNAL OF ORTHODONTICS
(2023)
Article
Gastroenterology & Hepatology
Jie Chen, Yajing Zhou, Yuhao Sun, Shuai Yuan, Rahul Kalla, Jing Sun, Jianhui Zhao, Lijuan Wang, Xuejie Chen, Xuan Zhou, Siqi Dai, Yu Zhang, Gwo-tzer Ho, Dajing Xia, Qian Cao, Zhanju Liu, Susanna C. Larsson, Xiaoyan Wang, Kefeng Ding, Jonas Halfvarson, Xue Li, Evropi Theodoratou, Jack Satsangi
Summary: This study identified 14 proteins associated with the risk of ulcerative colitis (UC) through the analysis of serum proteomic profiling data. Further analysis using Mendelian randomisation confirmed the causal relationship between two chemokines and the increased risk of UC. Additionally, a new protein associated with UC risk was identified. Reverse Mendelian randomisation analysis did not find any influence of genetic predisposition to UC on these three inflammation proteins.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Per Cajander, Taher Omari, Anders Magnuson, Harry Scheinin, Mika Scheinin, Johanna Savilampi
Summary: Dexmedetomidine affects pharyngeal swallowing and esophageal motility, which should be considered in clinical patient management and when choosing sedative agents for procedural sedation or manometric examination.
NEUROGASTROENTEROLOGY AND MOTILITY
(2023)
Article
Public, Environmental & Occupational Health
Irma Ahmad, Alicia Edin, Christoffer Granvik, Lowa Kumm Persson, Staffan Tevell, Emeli Mansson, Anders Magnuson, Ingela Marklund, Ida-Lisa Persson, Anna Kauppi, Clas Ahlm, Mattias N. E. Forsell, Josefin Sundh, Anna Lange, Sara Cajander, Johan Normark
Summary: This study investigated the prevalence of persistent symptoms and reduced health-related quality of life (HRQoL) in COVID-19 survivors at 6 months after infection. The results showed that 79% of hospitalized and 59% of non-hospitalized patients experienced persistent symptoms. Hospitalization was the most important risk factor for developing persistent symptoms, reduced HRQoL, and post-acute COVID syndrome (PACS+).
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Dentistry, Oral Surgery & Medicine
Farhan Bazargani, Vanessa Knode, Alexander Plaksin, Anders Magnuson, Bjoern Ludwig
Summary: This study compared the long-term skeletal effects of tooth-borne (TB) and tooth-bone-borne (TBB) rapid maxillary expansion in growing children using 3D imaging. The study found that the TBB group had significantly higher skeletal expansion in the midpalatal suture, but the magnitude of this expansion may not be clinically significant. The TBB group also had significantly larger expansion in the nasal width.
EUROPEAN JOURNAL OF ORTHODONTICS
(2023)
Article
Oncology
Kai Wang, Ola Olen, Louise Emilsson, Hamed Khalili, Jonas Halfvarson, Mingyang Song, Jonas F. Ludvigsson
Summary: This study examines the association between a history of inflammatory bowel disease (IBD) in first-degree relatives (FDRs) and the risk of colorectal cancer (CRC). The researchers conducted a case-control study in Sweden among 69,659 CRC cases and 343,032 non-CRC controls. They found that having FDRs with IBD history did not increase the risk of CRC. These findings suggest that extra screening for CRC may not be necessary in the relatives of IBD patients.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Genetics & Heredity
Zhanju Liu, Ruize Liu, Han Gao, Seulgi Jung, Xiang Gao, Ruicong Sun, Xiaoming Liu, Yongjae Kim, Ho-Su Lee, Yosuke Kawai, Masao Nagasaki, Junji Umeno, Katsushi Tokunaga, Yoshitaka Kinouchi, Atsushi Masamune, Wenzhao Shi, Chengguo Shen, Zhenglin Guo, Kai Yuan, Shu Zhu, Dalin Li, Jianjun Liu, Tian Ge, Judy Cho, Mark J. Daly, Dermot P. B. McGovern, Byong Duk Ye, Kyuyoung Song, Yoichi Kakuta, Mingsong Li, Hailiang Huang, Maria Abreu, Jean-Paul Achkar, Vibeke Andersen, Charles Bernstein, Steven R. Brant, Luis Bujanda, Siew Chien Ng, Judy Cho, Mark J. Daly, Lee A. Denson, Richard H. Duerr, Lynnette R. Ferguson, Denis Franchimont, Andre Franke, Richard Gearry, Hakon Hakonarson, Jonas Halfvarson, Caren Heller, Hailiang Huang, Antonio Julia, Judith Kelsen, Hamed Khalili, Subramaniam Kugathasan, Juozas Kupcinskas, Anna Latiano, Edouard Louis, Reza Malekzadeh, Jacob L. McCauley, Dermot P. B. McGovern, Christopher Moran, David Okou, Tim Orchard, Aarno Palotie, Miles Parkes, Joel Pekow, Uros Potocnik, Graham Radford-Smith, John D. Rioux, Gerhard Rogler, Bruce Sands, Mark Silverberg, Harry Sokol, Severine Vermeire, Rinse K. Weersma, Ramnik J. Xavier, Naizhong Hu, Qian Cao, Yufang Wang, Yinglei Miao, Hongjie Zhang, Xiaoping Lv, Xiang Gao, Hu Zhang, Jingling Su, Baisui Feng, Ye Zhao, Liangru Zhu, Yan Chen, Lanxiang Zhu, Chunxiao Chen, Yali Wang, Yingde Wang, Zhi Pang, Yingxuan Chen, Xiaolan Zhang, Hui Li, Qin Yu, Mei Ye, Sumin Zhang, Wen Tang, Mei Wang, Xiaocang Cao, Ruixin Zhu, Guangxi Zhou, Zhaolian Bian, Xiaofeng Guo, Xiaoli Wu, Jinchun Liu, Wei Xu, Yuqin Li, Qin Guo, Zhiguo Guo, Mingsong Li, Zhanju Liu
Summary: This study provides the largest investigation of inflammatory bowel diseases (IBDs) in individuals of East Asian ancestries, identifying 80 IBD loci, including 81 new loci. The study also discovers new IBD genes, such as ADAP1 and GIT2, and improves the accuracy of predicting IBD risk by incorporating data from both East Asian and European ancestries.
Article
Medicine, General & Internal
Jiangwei Sun, Fang Fang, Ola Olen, Mingyang F. Song, Jonas Halfvarson, Bjorn Roelstraete, Hamed Khalili, Jonas Ludvigsson
Summary: In this study, individuals who underwent endoscopic biopsy with normal mucosa were followed up for a median of 10 years. The study found that these individuals had an elevated risk of inflammatory bowel disease (IBD) for at least 30 years. These findings imply the presence of a substantial symptomatic period before the diagnosis of IBD and emphasize the importance of considering the long-term risk of IBD in patients with symptoms but normal mucosa on gastrointestinal investigation.
Article
Surgery
Erik Stenberg, Johan Ottosson, Anders Magnuson, Eva Szabo, Stefan Wallen, Erik Naeslund, Anders Thorell, Ingmar Naslund
Summary: This randomized clinical trial evaluated the long-term safety and efficacy of mesenteric defects closure during laparoscopic Roux-en-Y gastric bypass (LRYGB) surgery. The results showed a reduced risk of small bowel obstruction (SBO) with closure of mesenteric defects. Routine use of this procedure during LRYGB should be considered.
Article
Gastroenterology & Hepatology
Stefan Schreiber, Silvio Danese, Axel Dignass, Eugeni Domenech, Massimo C. Fantini, Marc Ferrante, Jonas Halfvarson, Ailsa Hart, Fernando Magro, Charlie W. Lees, Salvo Leone, Marieke J. Pierik, Michele Peters, Polly Field, Helen Fishpool, Laurent Peyrin-Biroulet
Summary: This international initiative used a Delphi process to review aspects of ulcerative colitis that affect patients and indicate mucosal inflammation, and reached a consensus on a definition of comprehensive disease control. The definition combines aspects currently measured in trials with additional patient-reported symptoms, and consensus was reached on scoring systems and thresholds for many aspects.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Joel Thunberg, Olle Granno, Daniel Bergemalm, Carl Eriksson, Isabella Visuri, Michael Eberhardson, Jonas Halfvarson
Summary: This study examined the agreement between a point-of-care test (POCT) by ProciseDx and the in-house enzyme-linked immunosorbent assay (ELISA) for infliximab (IFX) quantification. The results showed good agreement between the two methods, supporting the use of ProciseDx's POCT for rapid IFX quantification.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Isabella Visuri, Carl Eriksson, Sara Karlqvist, Byron Lykiardopoulos, Per Karlen, Olof Grip, Charlotte Soderman, Sven Almer, Erik Hertervig, Jan Marsal, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjoberg, Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson
Summary: This study assessed the long-term outcomes of vedolizumab in treating inflammatory bowel disease. The results showed that vedolizumab had high continuation rates and was associated with improvements in clinical outcomes, health-related quality of life measures, and inflammatory markers at 2 and 3 years after treatment initiation.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Archana Shubhakar, Bas C. Jansen, Alex T. Adams, Karli R. Reiding, Nicholas T. Ventham, Rahul Kalla, Daniel Bergemalm, Paulina A. Urbanowicz, Richard A. Gardner, Manfred IBD BIOM Consortium, Manfred Wuhrer, Jonas Halfvarson, Jack Satsangi, Daryl L. Fernandes, Daniel I. R. Spencer
Summary: This study investigated a composite serum N-glycomic biomarker to predict future disease course in newly diagnosed IBD patients. The biomarker showed a predictive capacity for treatment escalation in both the discovery and replication cohorts of patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Amiko M. Uchida, John J. Garber, Ashley Pyne, Kathryn Peterson, Bjorn Roelstraete, Ola Olen, Jonas Halfvarson, Jonas F. Ludvigsson
Summary: In this nationwide cohort study, EoE was found to be associated with a 3.5-fold increased risk of later IBD diagnosis, possibly due to genetic or early environmental risk factors.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)